2023
Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil
Pacheco S, Schinoni M, Stocker A, Paraná R, Reis M, Silva L. Prevalence of Genotypic Resistance Mutations in Patients with Chronic Hepatitis B (HBV) Treated with Entecavir and Tenofovir in Two Reference Centers in the North and Northeast of Brazil. Medical Research Archives 2023, 11 DOI: 10.18103/mra.v11i3.3473.Peer-Reviewed Original ResearchGenotypic resistance mutationsResistance mutationsHepatitis BChronic hepatitis BFirst-line treatmentVaccine escape mutationsHepatitis B virusChronic HBVAntiviral treatmentLine treatmentLiver diseaseTherapeutic managementB virusEscape mutationsGenotypic resistanceReference centerPatientsGenetic mutationsEntecavirHBVTenofovirTreatmentNortheast of BrazilPresent studyNucleotide analogues
2018
437. Spatial Distribution of Schistosomiasis After Repeated Praziquantel Treatments in a Rural Community in Brazil
Terashima R, Blanton R, Reis M. 437. Spatial Distribution of Schistosomiasis After Repeated Praziquantel Treatments in a Rural Community in Brazil. Open Forum Infectious Diseases 2018, 5: s165-s165. PMCID: PMC6255532, DOI: 10.1093/ofid/ofy210.447.Peer-Reviewed Original ResearchCommunity-wide treatmentSchistosomiasis prevalenceWater contact sitesPrevalence of schistosomiasisIndicator markersPrevalence of infectionTransmission persistsPraziquantel treatmentDistribution of infectionKato-KatzPrevalenceSchistosomiasisTreatment effortsStudy periodTreatmentPraziquantelRural communitiesInfectionMinimal fluctuationsMarkersMorbidityReinfectionStoolYearsDisease
2009
Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil.
Machado A, Finkmoore B, Emodi K, Takenami I, Barbosa T, Tavares M, Reis M, Arruda S, Riley L. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. The International Journal Of Tuberculosis And Lung Disease 2009, 13: 719-25. PMID: 19460247.Peer-Reviewed Original ResearchConceptsHousehold contactsLatent tuberculosis infectionLTBI treatmentLatent tuberculosis infection treatmentTB-endemic countriesRisks of treatmentHigh-risk populationPulmonary TBMedication intoleranceTuberculosis infectionTuberculosis controlRisk factorsHigh riskSide effectsInfection treatmentHospitalVisitsMonthsTreatmentFollowINHRiskTBRegimenPatients